Trial · Interventional
CompletedPhase 4Registry dataUse of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis
Overview
- Status
- Completed
- Phase
- Phase 4
- Enrollment
- 20 participants
- Sponsor
- Copenhagen University Hospital, Rigshospitalet · Other
- Design
- Not randomized · Open label (no masking)
- Countries
1 country
Denmark
- Start
- Jan 2005
- Primary completion
- Not stated
- Completion
- Not stated
- First posted
- 3 Feb 2006 (estimated)
- Last update posted
- 23 Apr 2007 (estimated)
- Conditions
- Endometriosis
Timeline
1 trial · 1 completed
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 4
Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis
NCT00286351Start Jan 2005
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome
Interventions
- Combined treatment with Arimidex and Zoladex before IVFDrug
Arms0
The registry lists no arms for this trial.
Primary outcomes1
Outcomes the sponsor listed as primary.
size of endometriomas after 2½ month of combined downregulation
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
Completed trials do not always post results.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- Female
- Age
- from 20 Years up to 40 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.